CEMI:NSD-Chembio Diagnostics Inc (USD)

COMMON STOCK | Diagnostics & Research | NSD

Last Closing Price

USD 0.37

Change

0.00 (0.00)%

Market Cap

USD 0.01B

Volume

0.38M

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict


CEMI Stock Forecast & Price:
Based on the Chembio Diagnostics Inc stock forecasts from 0 analysts, the average analyst target price for Chembio Diagnostics Inc is not available over the next 12 months. Chembio Diagnostics Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Chembio Diagnostics Inc is Bearish, which is based on 2 positive signals and 7 negative signals. At the last closing, Chembio Diagnostics Inc’s stock price was USD 0.37. Chembio Diagnostics Inc’s stock price has changed by -17.78% over the past week, -50.00% over the past month and -85.71% over the last year.

About Chembio Diagnostics Inc (CEMI:NSD)

Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. The company offers tests for COVID-19, HIV and Syphilis, and Zika virus. It also develops tests ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-09-24 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ILMN Illumina Inc

N/A

USD30.44B 43.58 82.40
IDXX IDEXX Laboratories Inc

N/A

USD28.14B 43.95 31.08
ICLR ICON PLC

N/A

USD16.76B 119.55 23.23
PRAH PRA Health Sciences, Inc

N/A

USD10.70B 50.52 25.79
EXAS EXACT Sciences Corporation

N/A

USD6.51B N/A -15.96
GH Guardant Health Inc

N/A

USD5.49B N/A -12.38
SYNH INC Research Holdings Inc

N/A

USD5.12B 19.23 12.10
MEDP Medpace Holdings Inc

N/A

USD4.81B 26.05 20.15
NTRA Natera Inc

N/A

USD4.51B N/A -8.15
NEOG Neogen Corporation

N/A

USD3.30B 35.47 37.01

ETFs Containing CEMI

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Diagnostics & Research)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -67.54% 35% F 19% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -67.54% 35% F 19% F
Trailing 12 Months  
Capital Gain -85.71% 17% F 11% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -85.71% 17% F 11% F
Trailing 5 Years  
Capital Gain -93.73% 28% F 6% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -93.73% 28% F 6% F
Average Annual (5 Year Horizon)  
Capital Gain -28.84% 11% F 7% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -28.84% 11% F 7% F
Risk Return Profile  
Volatility (Standard Deviation) 42.26% 58% F 34% F
Risk Adjusted Return -68.25% 19% F 12% F
Market Capitalization 0.01B 7% F 6% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Diagnostics & Research)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 0.64 91% A- 89% B+
Price / Cash Flow Ratio -0.39 33% F 43% F
EV/EBITDA -0.53 45% F 55% F
Management Effectiveness  
Return on Equity -206.10% 9% F 8% F
Return on Invested Capital -62.85% 32% F 21% F
Return on Assets -29.68% 23% F 16% F
Debt to Equity Ratio 51.33% 38% F 38% F
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 0.40 91% A- 82% B-
Short Percent 3.96% 50% F 36% F
Beta 1.65 24% F 18% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector